DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Information source: North Texas Veterans Healthcare System
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Myocardial Infarction

Intervention: Clopidogrel (Drug)

Phase: N/A

Status: Active, not recruiting

Sponsored by: North Texas Veterans Healthcare System

Official(s) and/or principal investigator(s):
Subhash Banerjee, MD, Principal Investigator, Affiliation: VA North Texas Healthcare System, UT Southwestern Medical Center
Emmanouil S Brilakis, MD, PhD, Study Director, Affiliation: VA North Texas Healthcare System, Dallas, TX

Summary

Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration of therapy after implantation of a drug eluting stents (DES). Current American College of Cardiology guidelines recommend clopidogrel use for at least one year in the absence of contraindications after DES implantation, while recognizing that the optimal duration remains unknown. While an extended clopidogrel therapy (that is beyond the current 1 year recommendation) may increase bleeding complication, it may reduce the rates of adverse cardiovascular events like heart attacks and repeat revascularization procedures. A clinical trial which randomizes patients with an uneventful one year course after a DES implantation, to an additional year of clopidogrel and aspirin therapy versus aspirin alone, will be able to answer the important question about the role of extended (2y) dual anti-platelet therapy with clopidogrel and aspirin after DES implants. The investigators hypothesize that clopidogrel discontinuation at 1 year post-DES implantation is associated with an increase in cardiovascular events during the one year of follow-up period.

Clinical Details

Official title: Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Death and Myocardial Infarction

Secondary outcome: Combined endpoints of death, myocardial infarction, repeat revascularization, stroke and major/minor bleeding

Detailed description: SCORE is a multicenter, prospective randomized study of post-percutaneous coronary intervention (PCI) patients with an uneventful 1 year post-PCI course on dual anti-platelet therapy (DAPT) with clopidogrel and aspirin. Patient will be randomized to an additional 1 year of DAPT (treatment arm) vs. aspirin alone (control arm)to assess the following endpoints during the 1 year follow-up period: 1. Death / Myocardial infarction (MI) (Primary end-point) 2. Combined endpoints of death, myocardial infarction, repeat revascularization, stroke, and major/minor bleeding (Secondary end-point) During the year of follow up, subjects will be contacted once every three months. This will enable us to track study endpoints in the study population. In addition the patients' medical records will be screened to investigate if any of the aforementioned endpoints have been reached.

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Post-PCI patients receiving at least 1 DES

- Completed 9-15 months follow-up free of MI, repeat revascularization

- Able to provide informed consent

- Have continued dual anti-platelet therapy with aspirin and clopidogrel for 1 year

post-PCI Exclusion Criteria:

- Patients allergic to aspirin

- Patients with aspirin resistance

- Patients with allergy to clopidogrel

- Patients on concomitant warfarin therapy

- History of bleeding diathesis, coagulopathy, and/or platelet count < 100,000 cubic

mm

- Patients with a life expectancy less than 1 year due to active cancers (except basal

cell carcinoma)

- Pregnancy

Locations and Contacts

The Onassis cardiac Surgery Centre, Athens, Greece

Escorts Health Institute & Research Centre Ltd, New Delhi, India

Dallas Veterans Hospital, Dallas, Texas 75216, United States

Additional Information

Related publications:

Banerjee S, Varghese C, Samuel J, Weideman RA, Little BB, Kelly KC, Rao SV, Reilly RF, Brilakis ES. Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol. 2008 Nov 1;102(9):1159-62. doi: 10.1016/j.amjcard.2008.06.058. Epub 2008 Sep 11.

Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, Jesse RA, Rumsfeld JS. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008 Feb 6;299(5):532-9. doi: 10.1001/jama.299.5.532. Erratum in: JAMA. 2008 May 28;299(20):2390.

Starting date: September 2008
Last updated: November 1, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017